Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity

Clinical and Vaccine Immunology

Volumn 19, Issue 7, 2012, Pages 991-998

  Uematsu, Yasushi ^a   Vajdy, Michael ^b,c   Lian, Ying ^b   Perri, Silvia ^b   Greer, Catherine E ^b   Legg, Harold S ^b   Galli, Grazia ^a   Saletti, Giulietta ^a   Otten, Gillis R ^b   Rappuoli, Rino ^a   Barnett, Susan W ^b   Polob, John M ^b,d  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Novartis Vaccines and Diagnostics Inc   (United States)

^c EpitoGenesis Inc   (United States)

^d XOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMORAL ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS HEMAGGLUTININ; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; SINDBIS VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INTERFERENCE;

ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINATION;

EID: 84863549346     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00031-12     Document Type: Article

References (55)

1. Altstein AD, et al. 2006. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch. Virol. 151:921-931.
2. Babiuk LA, Tikoo SK. 2000. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol. 83:105-113.
3. Barnett SW, et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985.
4. Barouch DH, et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297. (Pubitemid 38621236)
5. Bergen MJ, et al. 2010. Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One 5:e10297. doi:10.1371/journal.pone.0010297.
6. Bernstein DI, et al. 2009. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484-493.
7. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. 1993. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J. Virol. 67:6439-6446. (Pubitemid 23309108)
8. Casimiro DR, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replicationdefective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313. (Pubitemid 36588400)
9. Chen M, et al. 2002. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J. Immunol. 169:3208-3216. (Pubitemid 35013167)
10. Cottey R, Rowe CA, Bender BS. 2001. Influenza virus. Curr. Protoc. Immunol. 19:Unit 19.11.
11. Davis NL, et al. 2002. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53:209-211. (Pubitemid 34728929)
12. Dong M, et al. 2003. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J. Virol. 77:3119-3130. (Pubitemid 36228097)
13. Dubensky TW, Jr, et al. 1996. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:508-519.
14. Elliott MB, et al. 2007. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25:7132-7144. (Pubitemid 47464675)
15. Fitzgerald JC, et al. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170:1416-1422. (Pubitemid 36139509)
16. Gardner JP, et al. 2000. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 74:11849-11857. (Pubitemid 32222335)
17. Greer CE, et al. 2007. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. Scand. J. Immunol. 66:645-653. (Pubitemid 350132633)
18. Greer CE, et al. 2007. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25:481-489. (Pubitemid 44856090)
19. Gupta S, et al. 2005. Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J. Virol. 79:7135-7145. (Pubitemid 40677344)
20. Gupta S, et al. 2006. Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res. Hum. Retroviruses 22:993-997. (Pubitemid 46100684)
21. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113. (Pubitemid 30367531)
22. Hubby B, et al. 2007. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25:8180-8189. (Pubitemid 350046318)
23. Kadowaki N, et al. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869. (Pubitemid 32983021)
24. Kobinger GP, et al. 2006. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346:394-401. (Pubitemid 43357883)
25. Kowalski J, et al. 2007. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 25:2296-2305. (Pubitemid 46227692)
26. Kuka M, et al. 2010. Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists. PLoS One 5:e11491.
27. Liljestrom P, Garoff H. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 9:1356-1361.
28. Lodmell DL, Ewalt LC. 2000. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 18:2394-2398. (Pubitemid 30156810)
29. López-Macías C, et al. 2011. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29:7826-7834.
30. McCoy K, et al. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604. (Pubitemid 46878063)
31. Mok H, et al. 2007. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol. 81:13710-13722. (Pubitemid 350247864)
32. Montefiori DC. 2004. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in a luciferase reporter gene assay. Curr. Protoc. Immunol. 12:Unit 12-11.
33. Morse MA, et al. 2010. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J. Clin. Invest. 120:3234-3241.
34. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769-776. (Pubitemid 43090462)
35. Pan CH, et al. 2010. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J. Virol. 84:3798-3807.
36. Pan CH, et al. 2005. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 102:11581-11588. (Pubitemid 41170769)
37. Patterson LJ, Peng B, Nan X, Robert-Guroff M. 2004. Live adenovirus recombinants as vaccine vectors, p 325-335. In Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (ed), New generation vaccines, 3rd ed, revised and expanded. Marcel Dekker, Inc., New York, NY.
38. Perri S, et al. 2003. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77:10394-10403. (Pubitemid 37129683)
39. Polo JM, et al. 1999. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc. Natl. Acad. Sci. U. S. A. 96:4598-4603. (Pubitemid 29190382)
40. Pushko P, et al. 2010. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28:4771-4776.
41. Pushko P, et al. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401. (Pubitemid 28105644)
42. Reap EA, et al. 2007. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65 IE1 and gB proteins. Clin. Vaccine Immunol. 14:748-755. (Pubitemid 47104764)
43. Reap EA, et al. 2007. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25:7441-7449. (Pubitemid 47484007)
44. Schmeisser F, et al. 2012. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine 30:3413-3422.
45. Schultz-Cherry S, et al. 2000. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278 :55-59. (Pubitemid 32002594)
46. Sharpe S, et al. 2001. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing antivector immunity. J. Gen. Virol. 82:2215-2223. (Pubitemid 32827602)
47. Song HC, et al. 2004. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J. Virol. 78:10328-10335. (Pubitemid 39258358)
48. Stokes A, Tierney EL, Murphy BR, Hall SL. 1992. The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res. 25:91-103.
49. Tonkin DR, et al. 2010. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 28:3238-3246.
50. Vajdy M, et al. 2001. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J. Infect. Dis. 184:1613-1616. (Pubitemid 33139750)
51. White LJ, et al. 2007. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J. Virol. 81:10329-10339. (Pubitemid 47463308)
52. Williamson C, et al. 2003. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19:133-144. (Pubitemid 36308051)
53. Xiong C, et al. 1989. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243:1188-1191.
54. Xu R, et al. 2006. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res. Hum. Retroviruses 22:1022-1030. (Pubitemid 46100688)
55. zur Megede J, et al. 2006. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol and gagpol DNA and alphavirus replicon vaccines. Vaccine 24:2755-2763.